Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:28:16 ON 09 APR 2008

```
=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:28:37 ON 09 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    8 APR 2008  HIGHEST RN 1012980-81-2
DICTIONARY FILE UPDATES:   8 APR 2008  HIGHEST RN 1012980-81-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10545190\10545190a.str
```





chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-10 10-11 11-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 5-7 6-9 8-9 10-11 11-12
exact bonds :
7-8
isolated ring systems :
containing 1 :

G1:O,S,NH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



G1 O,S,NH

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:29:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2678 TO ITERATE

 74.7% PROCESSED   2000 ITERATIONS   10 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 50456 TO   56664
PROJECTED ANSWERS: 48 TO   486

L2   10 SEA SSS SAM L1

=> d scan

L2   10 ANSWERS   REGISTRY COPYRIGHT 2008 ACS on STN
IN   Urea, N-(5-chloro-2-phenoxyphenyl)-N'-[3-[8-[(4-
     pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-
MF   C31 H24 Cl N7 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Imidazo[1,2-a]pyrazin-8-amine, 6-phenyl-N-(3-pyridinylmethyl)-
MF C18 H15 N5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Imidazo[1,2-a]pyrazine-6-carboxamide, 8-[[(2-ethyl-6-methylphenyl)methyl]amino]-N-(2-methoxyethyl)-2,3-dimethyl-
MF C22 H29 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full
FULL SEARCH INITIATED 13:29:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 53781 TO ITERATE

100.0% PROCESSED 53781 ITERATIONS 232 ANSWERS
SEARCH TIME: 00.00.03

L3 232 SEA SSS FUL L1

=> d scan

L3 232 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Imidazo[1,2-a]pyrazin-8-amine, 6-[3-(dimethylamino)phenyl]-N-(3-pyridinylmethyl)-
MF C20 H20 N6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     178.82     179.03

FILE 'CAPLUS' ENTERED AT 13:29:33 ON 09 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 9 Apr 2008  VOL 148 ISS 15
FILE LAST UPDATED: 8 Apr 2008  (20080408/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4          47 L3

=> s l3 and (pd<=20030218 or ad<=20030218 or prd<=20030218)
            47 L3
      23674917 PD<=20030218
                 (PD<=20030218)
       4510797 AD<=20030218
                 (AD<=20030218)
       3986255 PRD<=20030218
                 (PRD<=20030218)
L5          29 L3 AND (PD<=20030218 OR AD<=20030218 OR PRD<=20030218)

=> d l5 1-29 ibib hitstr

L5   ANSWER 1 OF 29  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2006:463553  CAPLUS
DOCUMENT NUMBER:         144:488677
TITLE:                   Preparation of novel imidazopyrazines as cyclin
                         dependent kinase inhibitors
INVENTOR(S):             Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.;
                         Zhao, Lianyun; Curran, Patrick J.; Belanger, David B.;
                         Hamann, Blake; Reddy, Panduranga A.; Siddiqui, M.
                         Arshad
PATENT ASSIGNEE(S):      Schering Corporation, USA
SOURCE:                  U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S.
                         Ser. No. 47,524.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  2
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060106023	A1	20060518	US 2005-272392	20051110 <--
US 20040063715	A1	20040401	US 2003-665005	20030919 <--
US 6919341	B2	20050719		
US 20050130980	A1	20050616	US 2005-47524	20050131 <--
WO 2007058873	A2	20070524	WO 2006-US43592	20061108
WO 2007058873	A3	20070719		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2007200401	A1	20070222	AU 2007-200401		20070131
PRIORITY APPLN. INFO.:			US 2002-412997P	P	20020923 <--
			US 2003-665005	A3	20030919
			US 2005-47524	A2	20050131
			AU 2003-272476	A3	20030919
			US 2005-272392	A	20051110

OTHER SOURCE(S): MARPAT 144:488677

IT 676359-71-0P 676359-82-3P 676359-86-7P
676359-88-9P 676359-92-5P 676359-94-7P
676359-98-1P 676360-00-2P 676360-02-4P
676360-05-7P 676360-09-1P 676360-11-5P
676360-29-5P 676360-37-5P 676360-41-1P
676360-43-3P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases)

RN 676359-71-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 676359-82-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(tetrahydro-2-

furanyl)methyl]- (CA INDEX NAME)



RN 676359-86-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2-thienylmethyl)- (CA INDEX NAME)



RN 676359-88-9 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(cyclohexylmethyl)- (CA INDEX NAME)



RN 676359-92-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(1-phenylethyl)- (CA INDEX NAME)



RN 676359-94-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2-phenylethyl)- (CA INDEX NAME)



RN 676359-98-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2-phenylpropyl)- (CA INDEX NAME)



RN 676360-00-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 676360-02-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(3-chlorophenyl)methyl]- (CA INDEX NAME)



RN 676360-05-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[1-(4-chlorophenyl)ethyl]- (CA INDEX NAME)



RN 676360-09-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 676360-11-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2,2-diphenylethyl)- (CA INDEX NAME)



RN 676360-29-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-37-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(1-ethyl-2-

pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 676360-41-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 676360-43-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



IT 676359-53-8P 676360-96-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases)

RN 676359-53-8 CAPLUS
CN Ethanone, 1-[6-phenyl-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 676360-96-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-iodo-6-phenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



IT 676359-47-0P 676359-49-2P 676359-51-6P
676359-55-0P 676359-56-1P 676359-58-3P
676359-60-7P 676359-65-2P 676359-67-4P
676359-70-9P 676360-59-1P 676360-61-5P
676360-63-7P 676360-65-9P 676360-67-1P
676360-69-3P 676360-76-2P 676360-78-4P
676360-80-8P 676360-82-0P 676360-84-2P
676360-86-4P 676360-91-1P 676361-00-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases)

RN 676359-47-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3,6-diphenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676359-49-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-phenyl-N-(3-pyridinylmethyl)-3-(3-thienyl)- (CA INDEX NAME)



RN 676359-51-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-ethenyl-6-phenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676359-55-0 CAPLUS
CN Imidazo[1,2-a]pyrazine-3-methanol, α,α-dimethyl-6-phenyl-8-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



RN 676359-56-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676359-58-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 676359-60-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 676359-65-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 676359-67-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, N-(diphenylmethyl)-3-methyl- (CA INDEX NAME)



RN 676359-70-9 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-(5-pyrimidinylmethyl)- (CA INDEX NAME)



RN 676360-59-1 CAPLUS
CN 2-Piperidineethanol, 1-[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]- (CA INDEX NAME)



RN 676360-61-5 CAPLUS
CN Cyclohexanol, 2-[[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]amino]- (CA INDEX NAME)



RN 676360-63-7 CAPLUS
CN Cyclohexanemethanol, 2-[[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]amino]- (CA INDEX NAME)



RN 676360-65-9 CAPLUS
CN 1-Butanol, 2-[[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]amino]-3-methyl- (CA INDEX NAME)



RN 676360-67-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-(4-pyridinylmethyl)-
(CA INDEX NAME)



RN 676360-69-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-(3-pyridinylmethyl)-
(CA INDEX NAME)



RN 676360-76-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-[2-(4-pyridinyl)ethyl]-
(CA INDEX NAME)



RN 676360-78-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)



RN 676360-80-8 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-iodo-6-phenyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-82-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-84-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-chlorophenyl)-3-iodo-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-86-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-chlorophenyl)-3-iodo-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-91-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-chloro-6-(2-chlorophenyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676361-00-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



IT 887474-59-1P 887474-60-4P 887474-61-5P
887474-68-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases)

RN 887474-59-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(1-methyl-1H-pyrazol-4-yl)-N-(3-pyrrolidinylmethyl)- (CA INDEX NAME)



RN 887474-60-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(1-methyl-1H-pyrazol-4-yl)-N-(4-piperidinylmethyl)- (CA INDEX NAME)



RN 887474-61-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-(1-methyl-1H-pyrazol-4-yl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 887474-68-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]- (CA INDEX NAME)



L5 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:718541 CAPLUS
DOCUMENT NUMBER: 141:243569
TITLE: Preparation of 6-substituted imidazopyrazines with gastric antisecretory activity for treatment of gastrointestinal disorders
INVENTOR(S): Chiesa, M. Vittoria; Palmer, Andreas; Brehm, Christof; Grundler, Gerhard; Senn-Bilfinger, Joerg; Simon, Wolfgang-Alexander; Postius, Stefan; Kromer, Wolfgang; Zimmermann, Peter Jan; Buhr, Wilm
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074289	A1	20040902	WO 2004-EP50135	20040216 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004213177	A1	20040902	AU 2004-213177	20040216 <--
CA 2516021	A1	20040902	CA 2004-2516021	20040216 <--
EP 1599481	A1	20051130	EP 2004-711383	20040216 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007390	A	20060207	BR 2004-7390	20040216 <--
CN 1747956	A	20060315	CN 2004-80003928	20040216 <--
JP 2006517951	T	20060803	JP 2006-502029	20040216 <--
ZA 2005005670	A	20060426	ZA 2005-5670	20050714 <--
IN 2005MN00979	A	20060120	IN 2005-MN979	20050908 <--
NO 2005004199	A	20051117	NO 2005-4199	20050909 <--

US 20060148796 A1 20060706 US 2005-545190 20051109 <--
PRIORITY APPLN. INFO.: EP 2003-3652 A 20030218 <--
WO 2004-EP50135 A 20040216

OTHER SOURCE(S): MARPAT 141:243569

IT 750571-41-6P, 6-Bromo-8-[(2-ethyl-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyrazine 750571-42-7P, 6-Bromo-8-[(2-ethyl-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyrazine oxalate 750571-43-8P, Ethyl 8-[(2-ethyl-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxylate 750571-45-0P, 8-[(2-Ethyl-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxylic acid 750571-51-8P, 8-[(2-Ethyl-6-methylbenzyl)amino]-6-(hydroxymethyl)-2,3-dimethylimidazo[1,2-a]pyrazine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of imidazopyrazines with gastric antisecretory activity for treatment of gastrointestinal disorders)

RN 750571-41-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-bromo-N-[(2-ethyl-6-methylphenyl)methyl]-2,3-dimethyl- (CA INDEX NAME)



RN 750571-42-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-bromo-N-[(2-ethyl-6-methylphenyl)methyl]-2,3-dimethyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 750571-41-6
CMF C18 H21 Br N4



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 750571-43-8 CAPLUS
CN Imidazo[1,2-a]pyrazine-6-carboxylic acid, 8-[[(2-ethyl-6-methylphenyl)methyl]amino]-2,3-dimethyl-, ethyl ester (CA INDEX NAME)



RN 750571-45-0 CAPLUS
CN Imidazo[1,2-a]pyrazine-6-carboxylic acid, 8-[[(2-ethyl-6-methylphenyl)methyl]amino]-2,3-dimethyl- (CA INDEX NAME)



RN 750571-51-8 CAPLUS
CN Imidazo[1,2-a]pyrazine-6-methanol, 8-[[(2-ethyl-6-methylphenyl)methyl]amino]-2,3-dimethyl- (CA INDEX NAME)



IT 750571-44-9P, 6-[(Dimethylamino)carbonyl]-8-[(2-ethyl-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyrazine
750571-46-1P, 8-[(2-Ethyl-6-methylbenzyl)amino]-6-(pyrrolidinocarbonyl)-2,3-dimethylimidazo[1,2-a]pyrazine
750571-47-2P, 8-[(2-Ethyl-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide 750571-48-3P,
8-[(2-Ethyl-6-methylbenzyl)amino]-6-[(methylamino)carbonyl]-2,3-dimethylimidazo[1,2-a]pyrazine 750571-49-4P,
8-[(2-Ethyl-6-methylbenzyl)amino]-6-[[(2-methoxyethyl)amino]carbonyl]-2,3-dimethylimidazo[1,2-a]pyrazine 750571-50-7P,
8-[(2-Ethyl-6-methylbenzyl)amino]-6-[[(2-hydroxyethyl)amino]carbonyl]-2,3-dimethylimidazo[1,2-a]pyrazine 750571-52-9P,
8-[(2-Ethyl-6-methylbenzyl)amino]-6-(methoxymethyl)-2,3-dimethylimidazo[1,2-a]pyrazine hydrochloride 750571-53-0P,
8-[(2-Ethyl-6-methylbenzyl)amino]-6-(methoxymethyl)-2,3-dimethylimidazo[1,2-a]pyrazine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of imidazopyrazines with gastric antisecretory activity for treatment of gastrointestinal disorders)

RN 750571-44-9 CAPLUS
CN Imidazo[1,2-a]pyrazine-6-carboxamide, 8-[[(2-ethyl-6-methylphenyl)methyl]amino]-N,N,2,3-tetramethyl- (CA INDEX NAME)



RN 750571-46-1 CAPLUS
CN Methanone, [8-[[(2-ethyl-6-methylphenyl)methyl]amino]-2,3-dimethylimidazo[1,2-a]pyrazin-6-yl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 750571-47-2 CAPLUS
CN Imidazo[1,2-a]pyrazine-6-carboxamide, 8-[[(2-ethyl-6-methylphenyl)methyl]amino]-2,3-dimethyl- (CA INDEX NAME)



RN 750571-48-3 CAPLUS
CN Imidazo[1,2-a]pyrazine-6-carboxamide, 8-[[(2-ethyl-6-methylphenyl)methyl]amino]-N,2,3-trimethyl- (CA INDEX NAME)



RN 750571-49-4 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carboxamide, 8-[[(2-ethyl-6-methylphenyl)methyl]amino]-N-(2-methoxyethyl)-2,3-dimethyl- (CA INDEX NAME)



RN 750571-50-7 CAPLUS
CN Imidazo[1,2-a]pyrazine-6-carboxamide, 8-[[(2-ethyl-6-methylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (CA INDEX NAME)



RN 750571-52-9 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2-ethyl-6-methylphenyl)methyl]-6-(methoxymethyl)-2,3-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 750571-53-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2-ethyl-6-methylphenyl)methyl]-6-(methoxymethyl)-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:267339 CAPLUS
DOCUMENT NUMBER: 140:303700
TITLE: Preparation and pharmaceutical compositions of novel imidazopyrazines as cyclin dependent kinase inhibitors
INVENTOR(S): Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan K.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026877	A1	20040401	WO 2003-US29209	20030919 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2499756	A1	20040401	CA 2003-2499756	20030919	<--
AU 2003272476	A1	20040408	AU 2003-272476	20030919	<--
AU 2003272476	B2	20070705			
EP 1543008	A1	20050622	EP 2003-754658	20030919	<--
EP 1543008	B1	20071107			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1694886	A	20051109	CN 2003-825177	20030919	<--
JP 2006507253	T	20060302	JP 2004-537904	20030919	<--
AT 377600	T	20071115	AT 2003-754658	20030919	<--
NZ 538685	A	20080229	NZ 2003-538685	20030919	<--
ES 2293015	T3	20080316	ES 2003-754658	20030919	<--
MX 2005PA03120	A	20050622	MX 2005-PA3120	20050322	<--
ZA 2005002375	A	20050927	ZA 2005-2375	20050322	<--
HK 1072056	A1	20071221	HK 2005-105312	20050627	<--
AU 2007200401	A1	20070222	AU 2007-200401	20070131	

PRIORITY APPLN. INFO.:	US 2002-412997P	P	20020923 <--
	AU 2003-272476	A3	20030919
	WO 2003-US29209	W	20030919

OTHER SOURCE(S): MARPAT 140:303700

IT 676359-71-0P 676359-82-3P 676359-86-7P
676359-88-9P 676359-92-5P 676359-94-7P
676359-98-1P 676360-00-2P 676360-02-4P
676360-05-7P 676360-09-1P 676360-11-5P
676360-29-5P 676360-37-5P 676360-41-1P
676360-43-3P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; combinatorial preparation of a library of imidazopyrazines as cyclin dependent kinase inhibitors)

RN 676359-71-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 676359-82-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 676359-86-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2-thienylmethyl)- (CA INDEX NAME)



RN 676359-88-9 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(cyclohexylmethyl)- (CA INDEX NAME)



RN 676359-92-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(1-phenylethyl)- (CA INDEX NAME)



RN 676359-94-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2-phenylethyl)- (CA INDEX NAME)



RN 676359-98-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2-phenylpropyl)- (CA INDEX NAME)



RN 676360-00-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 676360-02-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(3-chlorophenyl)methyl]- (CA INDEX NAME)



RN 676360-05-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[1-(4-chlorophenyl)ethyl]- (CA INDEX NAME)



RN 676360-09-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 676360-11-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2,2-diphenylethyl)- (CA INDEX NAME)



RN 676360-29-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-37-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(1-ethyl-2-

pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 676360-41-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 676360-43-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



IT 676359-53-8P 676360-96-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)
RN 676359-53-8 CAPLUS
CN Ethanone, 1-[6-phenyl-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 676360-96-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-iodo-6-phenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



IT 676359-47-0P 676359-49-2P 676359-51-6P
676359-55-0P 676359-56-1P 676359-58-3P
676359-60-7P 676359-65-2P 676359-67-4P
676359-70-9P 676360-59-1P 676360-61-5P
676360-63-7P 676360-65-9P 676360-67-1P
676360-69-3P 676360-76-2P 676360-78-4P
676360-80-8P 676360-82-0P 676360-84-2P
676360-86-4P 676360-91-1P 676361-00-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)

RN 676359-47-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3,6-diphenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676359-49-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-phenyl-N-(3-pyridinylmethyl)-3-(3-thienyl)- (CA INDEX NAME)



RN 676359-51-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-ethenyl-6-phenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676359-55-0 CAPLUS
CN Imidazo[1,2-a]pyrazine-3-methanol, α,α-dimethyl-6-phenyl-8-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



RN 676359-56-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676359-58-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 676359-60-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 676359-65-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 676359-67-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, N-(diphenylmethyl)-3-methyl- (CA INDEX NAME)



RN 676359-70-9 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-(5-pyrimidinylmethyl)- (CA INDEX NAME)



RN 676360-59-1 CAPLUS
CN 2-Piperidineethanol, 1-[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]- (CA INDEX NAME)



RN 676360-61-5 CAPLUS
CN Cyclohexanol, 2-[[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]amino]- (CA INDEX NAME)



RN 676360-63-7 CAPLUS
CN Cyclohexanemethanol, 2-[[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]amino]- (CA INDEX NAME)



RN 676360-65-9 CAPLUS
CN 1-Butanol, 2-[[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]amino]-3-methyl- (CA INDEX NAME)



RN 676360-67-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-(4-pyridinylmethyl)-
(CA INDEX NAME)



RN 676360-69-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-(3-pyridinylmethyl)-
(CA INDEX NAME)



RN 676360-76-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-[2-(4-pyridinyl)ethyl]-
(CA INDEX NAME)



RN 676360-78-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)



RN 676360-80-8 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-iodo-6-phenyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-82-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-84-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-chlorophenyl)-3-iodo-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-86-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-chlorophenyl)-3-iodo-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-91-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-chloro-6-(2-chlorophenyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676361-00-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:267246 CAPLUS
DOCUMENT NUMBER: 140:303696
TITLE: Preparation and pharmaceutical compositions of novel imidazopyrazines as cyclin dependent kinase inhibitors
INVENTOR(S): Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004026310	A1	20040401	WO 2003-US29456	20030919 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499874	A1	20040401	CA 2003-2499874	20030919 <--
AU 2003275031	A1	20040408	AU 2003-275031	20030919 <--
US 20040072835	A1	20040415	US 2003-666424	20030919 <--
US 7186740	B2	20070306		
EP 1542693	A1	20050622	EP 2003-759300	20030919 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1694706	A	20051109	CN 2003-825102	20030919 <--
JP 2006503838	T	20060202	JP 2004-538213	20030919 <--
NZ 538686	A	20080131	NZ 2003-538686	20030919 <--
MX 2005PA03119	A	20050622	MX 2005-PA3119	20050322 <--
ZA 2005002380	A	20050927	ZA 2005-2380	20050322 <--
US 20070155751	A1	20070705	US 2007-680929	20070301 <--
PRIORITY APPLN. INFO.:			US 2002-412906P P	20020923 <--
			US 2003-666424 A3	20030919
			WO 2003-US29456 W	20030919

OTHER SOURCE(S): MARPAT 140:303696

IT 676132-50-6P 676132-51-7P 676132-52-8P
676132-53-9P 676132-54-0P 676132-55-1P
676132-56-2P 676132-57-3P 676132-58-4P
676132-59-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors)

RN 676132-50-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 6-methyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676132-51-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 6-(1,1-dimethylethyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676132-52-8 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-ethyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676132-53-9 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(cyclohexylmethyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676132-54-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(phenylmethyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676132-55-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-methyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676132-56-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(1,1-dimethylethyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676132-57-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-ethyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676132-58-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(cyclohexylmethyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676132-59-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(phenylmethyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:220337 CAPLUS
DOCUMENT NUMBER: 140:270878

TITLE: Kinase-modulating 6-aryl-imidazo[1,2-a]pyrazin-8-ylamines, method of their preparation, and method of their use, e.g., against cancer cells

INVENTOR(S): Desimone, Robert W.; Pippin, Douglas A.; Darrow, James W.; Mitchell, Scott A.; Currie, Kevin S.

PATENT ASSIGNEE(S): Cellular Genomics, Inc., USA

SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022562	A1	20040318	WO 2003-US28329	20030909 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003270489	A1	20040329	AU 2003-270489	20030909 <--
US 20040067951	A1	20040408	US 2003-658121	20030909 <--
US 7312341	B2	20071225		

PRIORITY APPLN. INFO.:	US 2002-409161P	P	20020909 <--
	WO 2003-US28329	W	20030909

OTHER SOURCE(S): MARPAT 140:270878

IT 618455-54-2P, 1-[4-[8-(2-Methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-phenylurea 618455-60-0P, (2-Methoxybenzyl)[6-[3-(4-methoxybenzylamino)phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 618455-66-6P, 1-(2-Chlorophenyl)-3-[4-[8-(2-methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 618455-69-9P, 1-[4-[8-(2-Methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(2-methoxyphenyl)urea 618455-71-3P, 1-[4-[8-(2-Methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-methoxyphenyl)urea 673857-09-5P, 3-Methoxy-N-[3-[8-(2-methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 673857-10-8P, 2-Methoxy-N-[3-[8-(2-methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 673857-12-0P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-[(pyridin-2-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673857-13-1P, 1-(4-Chlorophenyl)-3-[3-[8-[(pyridin-3-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673857-14-2P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-[(pyridin-3-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673857-15-3P , 1-(4-Chlorophenyl)-3-[3-[8-[(pyridin-4-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673857-16-4P, 1-[3-[8-[(Pyridin-4-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 673857-17-5P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-[(pyridin-4-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673857-20-0P, 1-(4-Chlorophenyl)-3-[3-[8-[(pyridin-2-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673857-21-1P, 1-[3-[8-[(Pyridin-2-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of arylimidazopyrazinylamines as kinase

modulators)

RN 618455-54-2 CAPLUS

CN Urea, N-[4-[8-[[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-phenyl- (CA INDEX NAME)



RN 618455-60-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2-methoxyphenyl)methyl]-6-[3-[[(4-methoxyphenyl)methyl]amino]phenyl]- (CA INDEX NAME)



RN 618455-66-6 CAPLUS

CN Urea, N-(2-chlorophenyl)-N'-[4-[8-[[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 618455-69-9 CAPLUS
CN Urea, N-(2-methoxyphenyl)-N'-[4-[8-[[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 618455-71-3 CAPLUS
CN Urea, N-(3-methoxyphenyl)-N'-[4-[8-[[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 673857-09-5 CAPLUS
CN Benzamide, 3-methoxy-N-[3-[8-[[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 673857-10-8 CAPLUS
CN Benzamide, 2-methoxy-N-[3-[8-[[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 673857-12-0 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[(2-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 673857-13-1 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 673857-14-2 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 673857-15-3 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[(4-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 673857-16-4 CAPLUS
CN Urea, N-[3-[8-[(4-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 673857-17-5 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[(4-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 673857-20-0 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[(2-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 673857-21-1 CAPLUS
CN Urea, N-[3-[8-[(2-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:855931 CAPLUS
DOCUMENT NUMBER: 139:350757
TITLE: Preparation of imidazo[1,2-a]pyrazin-8-ylamines as AKT-1 kinase inhibitors
INVENTOR(S): Desimone, Robert Walter, Jr.; Pippin, Douglas A.; Darrow, James W.
PATENT ASSIGNEE(S): Cellular Genomics, Inc., USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003089434	A2	20031030	WO 2003-US12222		20030421 <--
WO 2003089434	A3	20040115			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2482991	A1	20031030	CA 2003-2482991		20030421 <--
AU 2003221731	A1	20031103	AU 2003-221731		20030421 <--
US 20030212073	A1	20031113	US 2003-419682		20030421 <--
US 6919340	B2	20050719			
BR 2003009398	A	20050201	BR 2003-9398		20030421 <--
EP 1509526	A2	20050302	EP 2003-718470		20030421 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1668619	A	20050914	CN 2003-814467		20030421 <--
JP 2005530739	T	20051013	JP 2003-586154		20030421 <--
MX 2004PA10288	A	20050517	MX 2004-PA10288		20041018 <--
NO 2004004974	A	20041116	NO 2004-4974		20041116 <--
PRIORITY APPLN. INFO.:			US 2002-374213P	P	20020419 <--
			WO 2003-US12222	W	20030421

OTHER SOURCE(S): MARPAT 139:350757
IT 618455-08-6P 618455-13-3P 618455-19-9P
618455-25-7P 618455-36-0P 618455-41-7P
618455-47-3P 618455-50-8P 618455-54-2P
618455-57-5P 618455-60-0P 618455-63-3P
618455-66-6P 618455-69-9P 618455-71-3P
618455-82-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazo[1,2-a]pyrazin-8-ylamines as AKT-1 kinase inhibitors)
RN 618455-08-6 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[[(4-chlorophenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 618455-13-3 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[[(3-chlorophenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 618455-19-9 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[4-[8-[[(4-chlorophenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 618455-25-7 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[4-[8-[[(3-chlorophenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 618455-36-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, N-(cyclopropylmethyl)-6-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 618455-41-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2-methoxyphenyl)methyl]-6-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 618455-47-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, N-(1,3-benzodioxol-5-ylmethyl)-6-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 618455-50-8 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-[4-(chloromethyl)phenyl]-N-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 618455-54-2 CAPLUS
CN Urea, N-[4-[8-[[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-

yl]phenyl]-N'-phenyl- (CA INDEX NAME)



RN 618455-57-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2-methoxyphenyl)methyl]-6-[4-[[(4-methoxyphenyl)methyl]amino]phenyl]- (CA INDEX NAME)



RN 618455-60-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2-methoxyphenyl)methyl]-6-[3-[[(4-methoxyphenyl)methyl]amino]phenyl]- (CA INDEX NAME)



RN 618455-63-3 CAPLUS
CN Urea, N-[3-[8-[[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-

yl]phenyl]-N'-phenyl- (CA INDEX NAME)



RN 618455-66-6 CAPLUS
CN Urea, N-(2-chlorophenyl)-N'-[4-[8-[[(2-methoxyphenyl)methyl]amino]imidazo[
    1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 618455-69-9 CAPLUS
CN Urea, N-(2-methoxyphenyl)-N'-[4-[8-[[(2-methoxyphenyl)methyl]amino]imidazo
    [1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 618455-71-3 CAPLUS
CN Urea, N-(3-methoxyphenyl)-N'-[4-[8-[[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 618455-82-6 CAPLUS
CN Benzamide, N-[4-[3-methoxy-8-[[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



L5 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:818425 CAPLUS
DOCUMENT NUMBER: 139:337987
TITLE: Preparation of imidazothienopyrazines for treatment of inflammatory and immune diseases.
INVENTOR(S): Belema, Makonen; Bunker, Amy; Nguyen, Van; Beaulieu, Francis; Ouellet, Carl; Marinier, Anne; Roy, Stephan; Yang, Xuejie; Qiu, Yuping; Zhang, Yunhui; Martel, Alain; Zusi, Christopher
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 268 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003084959	A1	20031016	WO 2003-US9549		20030327 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003222106	A1	20031020	AU 2003-222106		20030327 <--
US 20040058930	A1	20040325	US 2003-400387		20030327 <--
US 6933294	B2	20050823			
EP 1490371	A1	20041229	EP 2003-718092		20030327 <--
EP 1490371	B1	20070815			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
AT 370145	T	20070915	AT 2003-718092		20030327 <--
ES 2291628	T3	20080301	ES 2003-718092		20030327 <--
PRIORITY APPLN. INFO.:			US 2002-369698P	P	20020403 <--
			WO 2003-US9549	W	20030327

OTHER SOURCE(S): MARPAT 139:337987
IT 615535-52-9P 615535-53-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazothienopyrazines for treatment of inflammatory and immune diseases)
RN 615535-52-9 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-bromo-3-methyl-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 615535-53-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-[2-(1-piperidinyl)ethyl]-6-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:594712 CAPLUS
DOCUMENT NUMBER: 137:150267
TITLE: Methods using pyrazine compounds and pyridine compounds for inhibiting JAK kinases, compound preparation, and therapeutic use
INVENTOR(S): Burns, Christopher John; Wilks, Andrew Frederick
PATENT ASSIGNEE(S): Cytopia Pty. Ltd., Australia
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060492	A1	20020808	WO 2002-AU89	20020130 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2436487	A1	20020808	CA 2002-2436487		20020130	<--
AU 2002226197	A1	20020812	AU 2002-226197		20020130	<--
EP 1363702	A1	20031126	EP 2002-715984		20020130	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
JP 2004528295	T	20040916	JP 2002-560683		20020130	<--
US 20040102455	A1	20040527	US 2003-470955		20030730	<--
US 20060069084	A1	20060330	US 2005-223633		20050909	<--
PRIORITY APPLN. INFO.:			AU 2001-2792	A	20010130	<--
			AU 2001-2793	A	20010130	<--
			WO 2002-AU89	W	20020130	<--
			US 2003-470955	A3	20030730	

OTHER SOURCE(S): MARPAT 137:150267

IT 445263-60-5 445263-61-6 445263-76-3
445263-77-4 445263-96-7 445263-97-8
445264-10-8 445264-14-2 445264-15-3
445264-22-2 445264-30-2 445264-31-3
445264-32-4 445264-38-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrazine compds. and pyridine compds. for inhibiting JAK kinases, compound preparation, and therapeutic use)

RN 445263-60-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-fluorophenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 445263-61-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, N-(2-pyridinylmethyl)-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 445263-76-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-[3,5-bis(trifluoromethyl)phenyl]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)



RN 445263-77-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-phenyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 445263-96-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(3-pyridinyl)-N-[2-(4-pyridinyl)ethyl]-
(CA INDEX NAME)



RN 445263-97-8 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-furanyl)-N-[2-(3-pyridinyl)ethyl]-
(CA INDEX NAME)



RN 445264-10-8 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-chlorophenyl)-N-(2-pyridinylmethyl)-
(CA INDEX NAME)



RN 445264-14-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(1-hexenyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 445264-15-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(1-hexenyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 445264-22-2 CAPLUS
CN Phenol, 5-[8-[(cyclopropylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]-2-methoxy- (CA INDEX NAME)



RN 445264-30-2 CAPLUS
CN Benzenepropanoic acid, 4-[8-[[2-(4-pyridinyl)ethyl]amino]imidazo[1,2-a]pyrazin-6-yl]- (CA INDEX NAME)



RN 445264-31-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-fluorophenyl)-N-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)



RN 445264-32-4 CAPLUS
CN Benzenepropanoic acid, 4-[8-[(2-furanylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]- (CA INDEX NAME)



RN 445264-38-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-(1H-indol-5-yl)-N-(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:375549 CAPLUS
DOCUMENT NUMBER: 131:19022
TITLE: Preparation of heterocyclic compounds for inhibition of gastric acid secretion
INVENTOR(S): Amin, Kosrat; Dahlstrom, Mikael; Nordberg, Peter; Starke, Ingemar
PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9928322	A1	19990610	WO 1998-SE2091	19981118 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9810468	A	19990521	ZA 1998-10468	19981116 <--
TW 515798	B	20030101	TW 1998-87118942	19981116 <--
CA 2311798	A1	19990610	CA 1998-2311798	19981118 <--
AU 9913565	A	19990616	AU 1999-13565	19981118 <--
AU 752187	B2	20020912		
BR 9814755	A	20001003	BR 1998-14755	19981118 <--
EP 1042324	A1	20001011	EP 1998-957270	19981118 <--

EP 1042324	B1	20030226				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO						
TR 200001530	T2	20001121	TR 2000-1530		19981118	<--
HU 2001000601	A2	20010928	HU 2001-601		19981118	<--
HU 2001000601	A3	20021028				
EE 200000315	A	20011015	EE 2000-315		19981118	<--
EE 4060	B1	20030616				
JP 2001525322	T	20011211	JP 2000-523214		19981118	<--
NZ 504355	A	20011221	NZ 1998-504355		19981118	<--
AT 233263	T	20030315	AT 1998-957270		19981118	<--
PT 1042324	T	20030630	PT 1998-957270		19981118	<--
ES 2191356	T3	20030901	ES 1998-957270		19981118	<--
CZ 292349	B6	20030917	CZ 2000-1947		19981118	<--
SK 283904	B6	20040406	SK 2000-674		19981118	<--
RU 2241000	C2	20041127	RU 2000-113729		19981118	<--
US 6518270	B1	20030211	US 2000-194823		20000208	<--
MX 2000PA05111	A	20011203	MX 2000-PA5111		20000524	<--
NO 2000002721	A	20000728	NO 2000-2721		20000526	<--
NO 315704	B1	20031013				
HK 1030216	A1	20030620	HK 2001-101145		20010216	<--
PRIORITY APPLN. INFO.:			SE 1997-4404	A	19971128	<--
			WO 1998-SE2091	W	19981118	<--

OTHER SOURCE(S): MARPAT 131:19022

IT 226721-20-6P 226721-23-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. for inhibition of gastric acid secretion)

RN 226721-20-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2,6-dimethylphenyl)methyl]-2,3-dimethyl- (CA INDEX NAME)



RN 226721-23-9 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-[(2,6-dimethylphenyl)methoxy]-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:144995 CAPLUS
DOCUMENT NUMBER: 126:139485
TITLE: Antiulcer Agents. 6. Analysis of the in Vitro Biochemical and in Vivo Gastric Antisecretory Activity of Substituted Imidazo[1,2-a]pyridines and Related Analogs Using Comparative Molecular Field Analysis and Hypothetical Active Site Lattice Methodologies
AUTHOR(S): Kaminski, James J.; Doweyko, Arthur M.
CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA
SOURCE: Journal of Medicinal Chemistry (1997), 40(4), 427-436
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 85333-40-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and structure-activity relations of substituted imidazopyridines and related analogs as antiulcer agents)
RN 85333-40-0 CAPLUS
CN Imidazo[1,2-a]pyrazine, 2,3-dimethyl-8-(phenylmethoxy)- (CA INDEX NAME)



IT 85333-46-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and structure-activity relations of substituted imidazopyridines and related analogs as antiulcer agents)
RN 85333-46-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:44647 CAPLUS
DOCUMENT NUMBER: 126:74840
TITLE: Preparation of imidazo[1,2-a]pyridines as bone resorption inhibitors
INVENTOR(S): Kawai, Yoshio; Satoh, Shigeki; Yamazaki, Hitoshi; Kayakiri, Natsuko; Yoshihara, Kousei; Oku, Teruo
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 9634866	A1	19961107	WO 1996-JP1103		19960423	<--
W: AU, CA, CN, JP, KR, MX, US						
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
AU 9653483	A	19961121	AU 1996-53483		19960423	<--
JP 11505524	T	19990521	JP 1996-533169		19960423	<--
PRIORITY APPLN. INFO.:			GB 1995-8826	A	19950501	<--
			GB 1995-12972	A	19950626	<--
			GB 1995-16647	A	19950814	<--
			WO 1996-JP1103	W	19960423	<--

OTHER SOURCE(S): MARPAT 126:74840
IT 185131-42-4P 185131-81-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazo[1,2-a]pyridines as bone resorption inhibitors)
RN 185131-42-4 CAPLUS
CN Benzamide, 2,6-dichloro-N-(2-methylimidazo[1,2-a]pyrazin-8-yl)- (CA INDEX NAME)



RN 185131-81-1 CAPLUS
CN Benzamide, N-(3-bromo-2-methylimidazo[1,2-a]pyrazin-8-yl)-2,6-dichloro-
(CA INDEX NAME)



L5 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:86801 CAPLUS
DOCUMENT NUMBER: 124:146154
TITLE: Preparation of imidazopyridine derivatives as bradykinin antagonists
INVENTOR(S): Oku, Teruo; Kayakiri, Hiroshi; Sato, Shigeki; Abe, Yoshito; Sawada, Yuki; Tanaka, Hirokazu
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07242666	A	19950919	JP 1994-37276	19940308 <--
PRIORITY APPLN. INFO.:			JP 1994-37276	19940308 <--

OTHER SOURCE(S): MARPAT 124:146154
IT 173159-26-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs. as bradykinin antagonists)
RN 173159-26-7 CAPLUS

CN Acetamide, N-[3-[[(3-bromo-2-methylimidazo[1,2-a]pyrazin-8-yl)oxy]methyl]-2,4-dichlorophenyl]-N-methyl- (CA INDEX NAME)



L5 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:74705 CAPLUS
DOCUMENT NUMBER: 114:74705
TITLE: Antiulcer agents. 5. Inhibition of gastric H+/K+-ATPase by substituted imidazo[1,2-a]pyridines and related analogs and its implication in modeling the high affinity potassium ion binding site of the gastric proton pump enzyme
AUTHOR(S): Kaminski, James J.; Wallmark, Bjorn; Briving, Carin; Andersson, Britt Marie
CORPORATE SOURCE: Dep. Chem. Res., Schering-Plough Corp., Bloomfield, NJ, 07003, USA
SOURCE: Journal of Medicinal Chemistry (1991), 34(2), 533-41
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 85333-46-6
RL: BIOL (Biological study)
(stomach ATPase and acid secretion inhibition by, mol. modeling in relation to)
RN 85333-46-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



L5 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:604675 CAPLUS
DOCUMENT NUMBER: 113:204675
TITLE: Structure and function of rat parietal cells during

treatment with omeprazole, SCH 28080, SCH 32651, or ranitidine
AUTHOR(S): Helander, H. F.; Mattsson, H.; Elm, G.; Ottosson, S.
CORPORATE SOURCE: Dep. Biol., AB Haessle, Molndal, Swed.
SOURCE: Scandinavian Journal of Gastroenterology (1990), 25(8), 799-809
CODEN: SJGRA4; ISSN: 0036-5521
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 85333-47-7, SCH 32651
RL: BIOL (Biological study)
(stomach parietal cell structure and function response to, as proton pump inhibitor)
RN 85333-47-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:526044 CAPLUS
DOCUMENT NUMBER: 113:126044
TITLE: Computer-automated structure evaluation of gastric antiulcer compounds: study of cytoprotective and antisecretory imidazo[1,2-a]pyridines and -pyrazines
AUTHOR(S): Klopman, Gilles; Srivastava, Sanjay
CORPORATE SOURCE: Dep. Chem., Case West. Reserve Univ., Cleveland, OH, 44106, USA
SOURCE: Molecular Pharmacology (1990), 37(6), 958-65
CODEN: MOPMA3; ISSN: 0026-895X
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 85333-46-6 85333-49-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiulcer activity of, computer-automated structure evaluation of)
RN 85333-46-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



RN 85333-49-9 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, N-ethyl-2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



L5 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:477237 CAPLUS
DOCUMENT NUMBER: 111:77237
TITLE: Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogs
AUTHOR(S): Kaminski, James J.; Puchalski, Chester; Solomon, Daniel M.; Rizvi, Razia K.; Conn, David J.; Elliott, Arthur J.; Lovey, Raymond G.; Guzik, Henry; Chiu, P. J. S.; et al.
CORPORATE SOURCE: Pharm. Res. Div., Schering Res., Bloomfield, NJ, 07003, USA
SOURCE: Journal of Medicinal Chemistry (1989), 32(8), 1686-700
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 111:77237
IT 85333-46-6
RL: PRP (Properties)
(gastric antisecretory and cytoprotective activity of)
RN 85333-46-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



L5 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:631072 CAPLUS

DOCUMENT NUMBER: 109:231072
ORIGINAL REFERENCE NO.: 109:38225a,38228a
TITLE: 8-Alkylaminoimidazo[1,2-a]pyrazine derivatives, their preparation, and their application in therapy
INVENTOR(S): Sablayrolles, Claire; Bonnet, Pierre Antoine; Cros, Gerard; Chapat, Jean Pierre; Boucard, Maurice
PATENT ASSIGNEE(S): Byk-Gulden Lomberg Chemische Fabrik G.m.b.H., Fed. Rep. Ger.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8804298	A1	19880616	WO 1987-EP756	19871204 <--
W: JP, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
FR 2607813	A1	19880610	FR 1986-17164	19861205 <--
FR 2607813	B1	19890331		
EP 348392	A1	19900103	EP 1988-900690	19871204 <--
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 02501575	T	19900531	JP 1988-500907	19871204 <--
US 5028605	A	19910702	US 1989-364428	19890602 <--

PRIORITY APPLN. INFO.: FR 1986-17164 A 19861205 <--
WO 1987-EP756 W 19871204 <--
OTHER SOURCE(S): CASREACT 109:231072; MARPAT 109:231072
IT 117718-79-3P 117718-81-7P 117736-93-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug)
RN 117718-79-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3,6-dibromo-N-(2-furanylmethyl)- (CA INDEX NAME)



RN 117718-81-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, N-(2-furanylmethyl)- (CA INDEX NAME)



RN 117736-93-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-bromo-N-(2-furanylmethyl)- (CA INDEX NAME)



L5 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:21791 CAPLUS
DOCUMENT NUMBER: 108:21791
ORIGINAL REFERENCE NO.: 108:3695a,3698a
TITLE: Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogs
AUTHOR(S): Kaminski, James J.; Hilbert, James M.; Pramanik, B. N.; Solomon, Daniel M.; Conn, David J.; Rizvi, Razia K.; Elliott, Arthur J.; Guzik, Henry; Lovey, Raymond G.; et al.
CORPORATE SOURCE: Pharm. Res. Div., Schering-Plough Corp., Bloomfield, NJ, 07003, USA
SOURCE: Journal of Medicinal Chemistry (1987), 30(11), 2031-46
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:21791
IT 110223-35-3P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal structure of)
RN 110223-35-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-, (2Z)-2-butenedioate (2:1) (CA INDEX NAME)

CM 1

CRN 85333-46-6
CMF C14 H14 N4 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT 85333-46-6P 85333-49-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and gastric antisecretory and cytoprotective activities of)
RN 85333-46-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



RN 85333-49-9 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, N-ethyl-2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



IT 85333-44-4P 110223-28-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 85333-44-4 CAPLUS

CN Imidazo[1,2-a]pyrazine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



RN 110223-28-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, N-ethyl-2-methyl-8-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:598179 CAPLUS
DOCUMENT NUMBER: 107:198179
ORIGINAL REFERENCE NO.: 107:31795a,31798a
TITLE: Antiulcer agents. 3. Structure-activity-toxicity relationships of substituted imidazo[1,2-a]pyridines and a related imidazo[1,2-a]pyrazine
AUTHOR(S): Kaminski, James J.; Perkins, D. G.; Frantz, J. D.; Solomon, Daniel M.; Elliott, Arthur J.; Chiu, P. J. S.; Long, James F.
CORPORATE SOURCE: Pharm. Res. Div., Schering-Plough Corp., Bloomfield, NJ, 07003, USA
SOURCE: Journal of Medicinal Chemistry (1987), 30(11), 2047-51
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 107:198179
IT 85333-46-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiulcer activity of)
RN 85333-46-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



L5 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:568562 CAPLUS
DOCUMENT NUMBER: 107:168562
ORIGINAL REFERENCE NO.: 107:26899a,26902a
TITLE: SCH 28080 is a more selective inhibitor than SCH 32651 at the potassium site of gastric potassium/proton ATPase
AUTHOR(S): Beil, Winfried; Starr, Ute; Sewing, Karl F.
CORPORATE SOURCE: Abt. Allg. Pharmakol., Med. Hochsch. Hannover, Hannover, D-3000, Fed. Rep. Ger.
SOURCE: European Journal of Pharmacology (1987), 139(3), 349-52
CODEN: EJPHAZ; ISSN: 0014-2999
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 85333-47-7, SCH 32651
RL: BIOL (Biological study)
(hydrogen/potassium ATPase of stomach inhibition by, antisecretory activity in relation to)
RN 85333-47-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



L5 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:138443 CAPLUS
DOCUMENT NUMBER: 106:138443
ORIGINAL REFERENCE NO.: 106:22593a,22596a
TITLE: Imidazopyridines and -pyrazines as antiulcer agents
INVENTOR(S): Ueda, Ikuo; Shiokawa, Youichi; Take, Kazuhiko; Itani, Hiromichi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 72 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 204285	A1	19861210	EP 1986-107418	19860602 <--
EP 204285	B1	19920115		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ZA 8603805	A	19870429	ZA 1986-3805	19860521 <--
US 4725601	A	19880216	US 1986-865331	19860521 <--
FI 8602210	A	19861205	FI 1986-2210	19860526 <--
DK 8602503	A	19861205	DK 1986-2503	19860528 <--
CA 1257264	A1	19890711	CA 1986-510496	19860530 <--
JP 62016483	A	19870124	JP 1986-128941	19860602 <--
AT 71625	T	19920215	AT 1986-107418	19860602 <--
NO 8602208	A	19861205	NO 1986-2208	19860603 <--
HU 40798	A2	19870227	HU 1986-2332	19860603 <--
CN 86104313	A	19870304	CN 1986-104313	19860603 <--
ES 555653	A1	19871201	ES 1986-555653	19860603 <--
AU 8658345	A	19861211	AU 1986-58345	19860604 <--
AU 593802	B2	19900222		
US 4782055	A	19881101	US 1986-942379	19861216 <--

PRIORITY APPLN. INFO.:		GB 1985-14080	A	19850604 <--
		GB 1985-30878	A	19851216 <--
		US 1986-865331	A2	19860521 <--
		EP 1986-107418	A	19860602 <--
		GB 1986-27736	A	19861120 <--

OTHER SOURCE(S): CASREACT 106:138443; MARPAT 106:138443

IT 107248-22-6P 107248-23-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiulcer agent)

RN 107248-22-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 2-methyl-N-[(2-methylphenyl)methyl]-3-(2-propynyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 107248-23-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 2-methyl-N-[(2-methylphenyl)methyl]-3-(2-propynyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:131501 CAPLUS
DOCUMENT NUMBER: 106:131501
ORIGINAL REFERENCE NO.: 106:21295a,21298a
TITLE: Studies on the mechanism of action of the gastric microsomal hydrogen ion-potassium-activated ATPase inhibitors SCH 32651 and SCH 28080
AUTHOR(S): Scott, Cynthia K.; Sundell, Erin; Castrovilly, Lorraine
CORPORATE SOURCE: Res. Lab., Ortho Pharm. Corp., Raritan, NJ, 08869, USA
SOURCE: Biochemical Pharmacology (1987), 36(1), 97-104
CODEN: BCPCA6; ISSN: 0006-2952
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 85333-47-7, SCH 32651
RL: BIOL (Biological study)
(ATPase inhibition by, in stomach, secretion inhibition in relation to)
RN 85333-47-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:626651 CAPLUS
DOCUMENT NUMBER: 105:226651
ORIGINAL REFERENCE NO.: 105:36607a,36610a
TITLE: 2-Methyl-3-amino-8-benzyloxyimidazo[1,2-a]pyrazine
INVENTOR(S): Gallardo Carrera, Antonio
PATENT ASSIGNEE(S): Fordonal S. A., Spain
SOURCE: Span., 7 pp.

CODEN: SPXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 537947	A1	19851101	ES 1984-537947	19841126 <--

PRIORITY APPLN. INFO.: ES 1984-537947 19841126 <--

IT 105545-75-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)
RN 105545-75-3 CAPLUS
CN Imidazo[1,2-a]pyrazine-3-carboxamide, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



IT 85333-46-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiulcer drug)
RN 85333-46-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



L5 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:14815 CAPLUS
DOCUMENT NUMBER: 104:14815
ORIGINAL REFERENCE NO.: 104:2417a,2420a
TITLE: Inhibition of hydrogen(+), potassium(+)-ATPase by SCH 28080 and SCH 32651
AUTHOR(S): Scott, Cynthia K.; Sundell, Erin
CORPORATE SOURCE: Res. Lab., Ortho Pharm. Corp., Raritan, NJ, 08869, USA
SOURCE: European Journal of Pharmacology (1985), 112(2), 268-70
CODEN: EJPHAZ; ISSN: 0014-2999
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 85333-47-7
RL: BIOL (Biological study)
(ATPase of stomach mucosa inhibition by, antisecretory mechanism in

relation to)
RN 85333-47-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:113532 CAPLUS
DOCUMENT NUMBER: 102:113532
ORIGINAL REFERENCE NO.: 102:17843a,17846a
TITLE: 8-(2-Imidazolylmethyloxy(thio, or amino))-imidazo[1,2-a]pyrazines and derivatives for treating hypertension
INVENTOR(S): Saari, Walfred S.
PATENT ASSIGNEE(S): Merck and Co., Inc. , USA
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4483858	A	19841120	US 1982-436753	19821025 <--

PRIORITY APPLN. INFO.: US 1982-436753 19821025 <--
OTHER SOURCE(S): CASREACT 102:113532; MARPAT 102:113532
IT 95185-86-7P 95185-91-4P 95185-92-5P
95185-93-6P 95186-08-6P 95186-09-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 95185-86-7 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 95185-91-4 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-[[(4,5-dihydro-1H-imidazol-2-yl)methyl]thio]- (CA INDEX NAME)



RN 95185-92-5 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-[[(1-methyl-1H-imidazol-2-yl)methyl]thio]- (CA INDEX NAME)



RN 95185-93-6 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]- (CA INDEX NAME)



RN 95186-08-6 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-[[(4,5-dihydro-1H-imidazol-2-yl)methyl]thio]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 95186-09-7 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-[[(1-methyl-1H-imidazol-2-yl)methyl]thio]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 95185-92-5
CMF C11 H11 N5 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L5 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:583783 CAPLUS
DOCUMENT NUMBER: 101:183783
ORIGINAL REFERENCE NO.: 101:27653a,27656a
TITLE: Gastric cytoprotective properties of SCH 32651, a novel antiulcer agent
AUTHOR(S): Chiu, P. J. S.; Barnett, A.; Gerhart, C.; Policelli, M.; Kaminski, J.
CORPORATE SOURCE: Dep. Pharmacol., Schering-Plough Corp., Bloomfield, NJ, USA
SOURCE: Archives Internationales de Pharmacodynamie et de Therapie (1984), 270(1), 128-40
CODEN: AIPTAK; ISSN: 0003-9780
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 85333-47-7
RL: BIOL (Biological study)
(antiulcer drug, cytoprotective properties of)
RN 85333-47-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



L5 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:583285 CAPLUS
DOCUMENT NUMBER: 101:183285
ORIGINAL REFERENCE NO.: 101:27553a,27556a
TITLE: Effects of SCH 32651 on resting and stimulated acid secretion in guinea-pig isolated fundic mucosa
AUTHOR(S): Barnett, Allen; Chiu, Peter J. S.; Tetzloff, Glen
CORPORATE SOURCE: Dep. Pharmacol., Schering-Plough Corp., Bloomfield, NJ, USA
SOURCE: British Journal of Pharmacology (1984), 83(1), 75-82

CODEN: BJPCBM; ISSN: 0007-1188
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 85333-47-7
RL: BIOL (Biological study)
(stomach mucosa acid secretion response to, mechanism of)
RN 85333-47-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:483791 CAPLUS
DOCUMENT NUMBER: 101:83791
ORIGINAL REFERENCE NO.: 101:12745a,12748a
TITLE: Gastric antisecretory properties of SCH 32651
AUTHOR(S): Chiu, P. J. S.; Barnett, A.; Tetzloff, G.; Kaminski, J.
CORPORATE SOURCE: Dep. Pharmacol., Schering-Plough Corp., Bloomfield, NJ, USA
SOURCE: Archives Internationales de Pharmacodynamie et de Therapie (1984), 270(1), 116-27
CODEN: AIPTAK; ISSN: 0003-9780
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 85333-47-7
RL: BIOL (Biological study)
(gastric antisecretory properties of)
RN 85333-47-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1983:438461 CAPLUS
DOCUMENT NUMBER: 99:38461
ORIGINAL REFERENCE NO.: 99:6045a,6048a
TITLE: Imidazo[1,2-a]pyridines and pyrazines and pharmaceutical compositions containing them
INVENTOR(S): Bristol, James Arthur; Puchalski, Chester; Lovey, Raymond George
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: Eur. Pat. Appl., 77 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 68378	A1	19830105	EP 1982-105411	19820621 <--
EP 68378	B1	19860305		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4507294	A	19850326	US 1982-356052	19820308 <--
AT 18402	T	19860315	AT 1982-105411	19820621 <--
DK 8202844	A	19821227	DK 1982-2844	19820624 <--
FI 8202266	A	19821227	FI 1982-2266	19820624 <--
FI 73433	B	19870630		
FI 73433	C	19871009		
NO 8202128	A	19821227	NO 1982-2128	19820624 <--
NO 159724	B	19881024		
NO 159724	C	19890201		
AU 8285178	A	19830106	AU 1982-85178	19820624 <--
AU 556062	B2	19861023		
ZA 8204516	A	19840229	ZA 1982-4516	19820624 <--
JP 58013584	A	19830126	JP 1982-109694	19820625 <--
JP 04004318	B	19920127		
HU 28470	A2	19831228	HU 1982-2071	19820625 <--
HU 189595	B	19860728		
IL 66141	A	19870227	IL 1982-66141	19820625 <--
CA 1248957	A1	19890117	CA 1982-406007	19820625 <--
US 4450164	A	19840522	US 1982-450885	19821220 <--
CA 1202630	A1	19860401	CA 1983-423133	19830308 <--

PRIORITY APPLN. INFO.:

US 1981-277576	A	19810626 <--
US 1982-356052	A	19820308 <--
US 1980-114473	A2	19800123 <--
ZA 1981-219	A	19810113 <--
EP 1982-105411	A	19820621 <--

OTHER SOURCE(S): CASREACT 99:38461; MARPAT 99:38461
IT 85333-44-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and nitrosation of)
RN 85333-44-4 CAPLUS
CN Imidazo[1,2-a]pyrazine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



IT 85333-45-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 85333-45-5 CAPLUS
CN Imidazo[1,2-a]pyrazine, 2-methyl-3-nitroso-8-(phenylmethoxy)- (CA INDEX NAME)



IT 85333-40-0P 85333-46-6P 85333-47-7P
85333-48-8P 85333-49-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 85333-40-0 CAPLUS
CN Imidazo[1,2-a]pyrazine, 2,3-dimethyl-8-(phenylmethoxy)- (CA INDEX NAME)



RN 85333-46-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



RN 85333-47-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 85333-48-8 CAPLUS
CN Imidazo[1,2-a]pyrazine-3-acetonitrile, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



RN 85333-49-9 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, N-ethyl-2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



=>

=>

=>

=>

=>

=>
=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	129.99	309.02

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:48:24 ON 09 APR 2008